AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

For years, the healthcare industry has been a cornerstone of the economy, offering resilience in both stable and uncertain ...

The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena ...

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, ...

AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection. However, the shares look pricey at the moment. AbbVie is known as ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

The Food and Drug Administration recently intervened regarding a migraine medication ad featuring tennis superstar Serena ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

AbbVie has filed a lawsuit against BeiGene, alleging the biotechnology company of stealing trade secrets to develop a competing cancer therapy.

According to a letter released by the FDA, the advertisement makes false or misleading claims about the drug's efficacy in treating migraine pain. The agency added that the ad exaggerates the speed ...

The accelerated approval submission for Teliso-V will be reviewed under FDA's real-time oncology review program with an approval decision anticipated in 2025. AbbVie announced FDA breakthrough ...